Proton pump inhibitor therapy predisposes to community‐acquired Streptococcus pneumoniae pneumonia
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Summary: Background: The pathophysiological mechanisms which contribute to an increased risk of community‐acquired pneumonia (CAP) in patients using proton pump inhibitors are not well established. Aim: To examine differences in microbial etiology in patients with CAP between patients with and without proton pump inhibitor (PPI) therapy and its possible impact on disease severity. Methods: All individuals consulting the emergency care unit were prospectively registered and underwent chest radiography. Sputum, urine, nose‐throat swabs and blood samples were obtained for microbial evaluation. We evaluated the association between use of proton pump inhibitors, etiology of CAP and severity of illness with multivariate regression analysis. Results: The final cohort comprised 463 patients, 29% using proton pump inhibitors (PPI s). Pathogens regarded as oropharyngeal flora were more common in CAP patients using PPI therapy compared to those who did not (adjusted OR: 2.0; 95% CI: 1.22–3.72). Patients using proton pump inhibitors more frequently had an infection with S treptococcus pneumoniae (28% vs. 14%) and less frequently with C oxiella burnetii (8% vs. 19%) compared to nonuser of PPI. Adjusted for baseline differences, the risk of PPI users being infected with S. pneumonia was 2.23 times (95% CI: 1.28–3.75) higher compared to patients without PPI's. No risk between PPI use and any other microbial pathogen was found. There was no difference in severity of CAP between patients with and without using PPI therapy. Conclusions: Proton pump inhibitor therapy was associated with an approximately 2‐fold increased risk to develop community‐acquired pneumonia possibly as a result of S. pneumoniae infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-456so · Cited by 4,925 · cited 1×
“91) Mycoplasma pneumonia 43 (13) 11 (8) 0.”
Acid-suppressive medication use and the risk for hospital-acquired pneumonia
Herzig, S. J. (2009) · JAMA · doi:10.1001/jama.2009.722 · Cited by 486 · cited 2×
“Oropharyngeal flora‡ 69 (21) 50 (38) 2.”
Bavishi, C., & DuPont, H. L. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04874.x · Cited by 480
Cited by
Proton pump inhibitors alter the composition of the gut microbiota
Jackson, M. A., Goodrich, J. K., Maxan, M.-E., Freedberg, D. E., Abrams, J. A., Poole, A. C., Sutter, J. L., Welter, D., Ley, R. E., Bell, J. T., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310861 · Cited by 895
Mullish, B. H., Quraishi, M. N., Segal, J. P., McCune, V. L., Baxter, M., Marsden, G. L., Moore, D. J., Colville, A., Bhala, N., Iqbal, T. H., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-316818 · Cited by 332
Barrett Esophagus and Risk of Esophageal Cancer: A Clinical Review
Spechler, S. J. (2013) · JAMA · doi:10.1001/jama.2013.226450 · Cited by 284
Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications
Le Bastard, Q., Al‐Ghalith, G. A., Grégoire, M., Chapelet, G., Javaudin, F., Dailly, E., Batard, E., Knights, D., & Montassier, E. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14451 · Cited by 263
Anti-Acid Drug Treatment Induces Changes in the Gut Microbiome Composition of Hemodialysis Patients
Lin, Y.-T., Lin, T.-Y., Hung, S.-C., Liu, P.-Y., Wu, P.-H., Chuang, Y.-S., Hung, W.-C., Chiu, Y.-W., Kuo, M.-C., & Wu, C.-Y. (2021) · Microorganisms · doi:10.3390/microorganisms9020286 · Cited by 22
“A significantly increased risk of community-acquired pneumonia has been observed with PPIs [45], specifically for Streptococcus-derived pneumonia [46].”
Background
Metadata
- Authors
- de Jager, C. P. C., Wever, P. C., Gemen, E. F. A., van Oijen, M. G. H., van Gageldonk‐Lafeber, A. B., Siersema, P. D., Kusters, G. C. M., & Laheij, R. J. F.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2012-10-03
- Volume
- 36
- Issue
- 10
- Pages
- 941-949
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2170074113
- Cited by
- 76
- References
- 3
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proton pump inhibitor therapy predisposes to community‐acquired Streptococcus pneumoniae pneumonia. https://app.cochat.ai/papers/10.1111/apt.12069
- The paper
- de Jager, C. P. C., Wever, P. C., Gemen, E. F. A., van Oijen, M. G. H., van Gageldonk‐Lafeber, A. B., Siersema, P. D., Kusters, G. C. M., & Laheij, R. J. F. (2012). Proton pump inhibitor therapy predisposes to community‐acquired Streptococcus pneumoniae pneumonia. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.12069
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.